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Dabigatran Etexilate and Risk of Myocardial Infarction, Other
Cardiovascular Events, Major Bleeding, and All-Cause Mortality:
A Systematic Review and Meta-analysis of Randomized Controlled
Trials
Jonathan Douxﬁls, PharmD; Fanny Buckinx, MS; Francois Mullier, PharmD, PhD; Valentine Minet, PharmD; Veronique Rabenda, MSc;
Jean-Yves Reginster, MD, PhD; Philippe Hainaut, MD, PhD; Olivier Bruyere, PhD; Jean-Michel Dogne, PharmD, PhD
Background-—Signals of an increased risk of myocardial infarction (MI) have been identiﬁed with dabigatran etexilate in
randomized controlled trials (RCTs).
Methods and Resules-—We conducted searches of the published literature and a clinical trials registry maintained by the drug
manufacturer. Criteria for inclusion in our meta-analysis included all RCTs and the availability of outcome data for MI, other
cardiovascular events, major bleeding, and all-cause mortality. Among the 501 unique references identiﬁed, 14 RCTs fulﬁlled the
inclusion criteria. Stratiﬁcation analyses by comparators and doses of dabigatran etexilate were conducted. Peto odds ratio
(ORPETO) values using the ﬁxed-effect model (FEM) for MI, other cardiovascular events, major bleeding, and all-cause mortality were
1.34 (95% CI 1.08 to 1.65, P=0.007), 0.93 (95%CI 0.83 to 1.06, P=0.270), 0.88 (95% CI 0.79 to 0.99, P=0.029), and 0.89 (95% CI
0.80 to 1.00, P=0.041). When compared with warfarin, ORPETO values using FEM were 1.41 (95% CI 1.11 to 1.80, P=0.005), 0.94
(95%CI 0.83 to 1.06, P=0.293), 0.85 (95% CI 0.76 to 0.96, P=0.007), and 0.90 (95% CI 0.81 to 1.01, P=0.061), respectively. In
RCTs using the 150-mg BID dosage, the ORPETO values using FEM were 1.45 (95% CI 1.11 to 1.91, P=0.007), 0.95 (95% CI 0.82 to
1.09, P=0.423), 0.92 (95% CI 0.81 to 1.05, P=0.228), and 0.88 (95% CI 0.78 to 1.00, P=0.045), respectively. The results of the
110-mg BID dosage were mainly driven by the RE-LY trial.
Conclusions-—This meta-analysis provides evidence that dabigatran etexilate is associated with a signiﬁcantly increased risk of MI.
This increased risk should be considered taking into account the overall beneﬁt in terms of major bleeding and all-cause mortality.
( J Am Heart Assoc.2014;3:e000515 doi: 10.1161/JAHA.113.000515)
Key Words: all-cause mortality • dabigatran etexilate • major bleeding • myocardial infarction
D abigatran etexilate, the prodrug of dabigatran, an oraldirect thrombin inhibitor, is used in Europe and Canada
for the prevention of venous thromboembolic events in
major orthopaedic surgery. Based on the results of the RE-
LY study (Randomized Evaluation of Long-term anticoagulant
therapY with dabigatran etexilate), dabigatran etexilate has
also been approved for prevention of stroke and systemic
embolism in adult patients with nonvalvular atrial ﬁbrillation
(NVAF) by both the European Commission and the Food
and Drug Administration (FDA) as well as in many countries
worldwide. Interestingly, myocardial infarction (MI) rates
were increased with dabigatran etexilate 110 mg BID and
150 mg BID compared with warfarin. This concern over the
increase in MI with dabigatran etexilate has prompted an
additional detailed analysis where there was no excess of
new angina hospitalizations or revascularization in dabiga-
tran etexilate–treated patients. The net clinical beneﬁt,
deﬁned as a composite of stroke, MI, cardiovascular death,
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pulmonary embolism, systemic embolic event, and major
bleeding, was in favor of dabigatran etexilate with a rate by
1000 person-years of 73.4, 71.1, and 79.1 for dabigatran
etexilate 150 mg BID, dabigatran etexilate 110 mg BID,
and warfarin, respectively.1 A recent systematic review and
meta-analysis of the literature evaluating the safety and
efﬁcacy of the non–vitamin K antagonist (VKA) oral antico-
agulants (NOACs) in atrial ﬁbrillation (AF) showed a signif-
icant reduction in total and cardiovascular mortality as well
as in the composite outcome of stroke and systemic
embolism. No difference in MI was observed. Nevertheless,
the fact that all NOACs were pooled together and that only
AF population was included, prevents the assessment of the
risk related to a speciﬁc product.2
The risk of MI associated with the use of dabigatran
etexilate was assessed in a previous meta-analysis of 7
noninferiority randomized controlled trials (RCTs) showing a
signiﬁcant 33% increase in MI corresponding to an absolute
risk increase of 0.27% during follow-up.3 Unfortunately, this
analysis incorporated the initial RE-LY publication and did
not take into account the additional events subsequently
reported.4 Moreover, the study only included 7 RCTs and did
not take into account studies having not demonstrated
noninferiority (ie, the RE-MOBILIZE trial).5 Another recently
published meta-analysis, including these additional events as
well as data from more recent studies, demonstrated once
again an overall signiﬁcant 30% increase of MI. This meta-
analysis also evaluated other NOACs, especially apixaban and
rivaroxaban. Nevertheless, even if stratiﬁcation by indication
of use was performed, no information about the risk stratiﬁed
by dose of dabigatran etexilate or comparator was provided.6
Moreover, the most recent studies were not included (ie,
RE-COVER II and RE-ALIGN).7,8
Thus, the question of whether dabigatran etexilate causes
MI or is less efﬁcacious than warfarin or other active
comparators for the prevention of such events remains
unanswered. Today, there is a need for regulators and
clinicians to have robust evidence on the potential increased
risk of MI when dabigatran etexilate at either a high or a low
dose is compared with other anticoagulants or placebo. The
need for a more-detailed analysis of the effects of dabigatran
on coronary events against the different comparators was
pointed out by Holnloser et al1 Therefore, we performed a
meta-analysis of RCTs comparing dabigatran etexilate with
active comparators versus placebo to assess the effect of this
agent on MI risk as a primary objective. The outcome of other
cardiovascular events, major bleeding, and all-cause mortality
was also assessed to provide global safety and efﬁcacy
measure. Stratiﬁcations by comparators (enoxaparin, warfa-
rin, or placebo) were performed. Additional analyses with
studies using the 2 licensed doses in the European Union for
AF (150 mg BID and 110 mg BID) were also provided.
Methods
Analyzed Studies
The primary aim of this meta-analysis was to assess the risk
of MI, other cardiovascular events, major bleeding, and all-
cause mortality associated with the use of dabigatran
etexilate. We extracted the data from published RCTs mainly
due to the fact that a meta-analysis based on individual data
would have been too complicated to establish since we did
not have access to the data from each RCTs. Therefore, we
performed an exhaustive meta-analysis based on data
provided in the literature or available in speciﬁc registries
(ClinicalTrial.gov and the registry maintained by Boerhinger
Ingelheim).
Eligibility Criteria
To be included in the meta-analysis, clinical trials should
present the following criteria: (1) it should be an RCT and (2)
the follow-up should have been the same between the
different groups. In addition, (3) the control groups should
receive a placebo or the reference treatment when applicable.
This meant (3a) warfarin was the reference treatment in
patients with NVAF and in the treatment of venous thrombo-
embolism (VTE) or pulmonary embolism; (3b) enoxaparin was
the reference treatment for the prevention of VTE events in
patients undergoing total hip or knee surgery; and (3c)
placebo was used for the prevention of recurrence of coronary
events in patients receiving antiplatelet therapy or for the
prevention of recurrence of VTE events in patients who had
completed a ﬁrst period of anticoagulant therapy.
Literature Search
We conducted a literature search of journal articles in 3
different databases (PubMed, Scopus, and The Cochrane
Database–Trials Results) published on or before December 8,
2013, assessing dabigatran etexilate versus control group in
RCTs. The following key words were used: “dabigatran,”
“dabigatran etexilate,” “BIBR 1048,” “randomized controlled
trial,” “randomized clinical trial,” “randomized trial,” “rando-
mised controlled trial,” “randomised clinical trial,” or “rando-
mised trial” (see Supporting information for the complete
literature search). We considered only English-language
publications. We also searched for abstracts published during
the past 3 years at international congresses (American Heart
Association, International Society on Thrombosis and Hae-
mostasis, and American Society of Haematology). Moreover,
we performed a hand search of all the references of previous
meta-analyses of RCTs with dabigatran etexilate.3,9 The initial
search of the 3 databases was performed by JD; the
references obtained were screened independently by 2
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investigators (JD and FB). The reason for exclusion was noted
for rejected articles (Figure 1). Consensus for inclusion was
reached after assessment by an other reviewer (JMD). Data
were encoded by an independent analyst (VR).
Outcome Deﬁnitions
Table 1 summarizes outcomes deﬁnitions provided in
included RCTs. For all outcomes of interest (ie, MI, other
cardiovascular events, major bleeding, and all-cause mortal-
ity), we referred to the deﬁnition provided the studies to
identify and extract the data.
Table 2 identiﬁes all outcomes of interest provided in the
included RCTs. When speciﬁed, only MI was considered for
inclusion. With the exception of the RE-DEEM, RE-COVER, and
RE-MEDY trials and the updated results of the RE-LY
study,1,4,10–12 included trials did not describe adjudication
of MI or other cardiovascular events. Thus, when unspeciﬁed,
acute coronary syndromes (ACS) or cardiac serious adverse
events were classiﬁed as MI for conservative purposes. When
adjudicated, fatal MI events were not added in the MI group
since they were already counted as MI in trials identiﬁed in
the meta-analysis (eg, in the RE-LY trial, fatal MI was
considered as MI leading to death within 30 days).1 For the
RE-DEEM trial, we only included nonfatal MI since cardiovas-
cular death included cardiac fatal outcome other than MI.10
When speciﬁed, other cardiovascular events were deﬁned as
unstable angina; cardiac arrest; cardiac death including
sudden death, arrhythmic death, pump failure of post-MI;
coronary artery bypass graft surgery; and percutaneous
coronary intervention. Importantly, the deﬁnition of major
bleeding varied among studies. Therefore, we use the
deﬁnition of major bleeding proposed within each study.
Data Extraction
Information was extracted from each included trial on (1) study
design and other information (year of publication, design),
(2) characteristics of trial participants (including number of
patients, age, sex), (3) type of intervention (including type,
PubMed:
70 Articles
Scopus:
401 Articles
The Cochrane 
Database: 
48 Articles
35 Articles or 
abstracts eligible 
for further analysis
• 21 Duplicates were removed
• 1 abstract removed: The treatment 
was not randomly assigned
Abstracts from 
International 
Congress:
2 Abstracts
12 Full-text Articles 
and 1 abstract* 
assessed for 
eligibility 
12 Full-text articles 
and 1 abstract* 
included in 
qualitative 
synthesis
12 Full-text articles 
and 1 abstract* 
included in 
qualitative 
synthesis (meta-
analysis)
Id
en
tif
ic
at
io
n
Sc
re
en
in
g
E
lig
ib
ili
ty
In
cl
us
io
n
* The abstract has become
published as a full-text
article after the deadline
inclusion. Therefore, data
were extracted from the
article in order to provide
updated information.
Figure 1. PRISMA (preferred reporting items for systematic reviews and meta-analysis) ﬂow diagram of study selection.
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duration, control and dabigatran etexilate regimens), and data
on (4) MI, (5) other cardiovascular events, (6) major bleeding
and (7) all-cause mortality, when available. When no informa-
tion concerning MI, other cardiovascular events, major
bleeding, or all-cause mortality was available, corresponding
authors were contacted to collect missing data, with a
reminder after 15 days.
Secondary Analysis
Stratiﬁcation by comparators and a speciﬁc analysis of 2
European Union–licensed doses of dabigatran etexilate for
NVAF (ie, the 150 mg BID and 110 mg BID dosage regimens)
were performed as secondary analysis. In the primary analysis,
multiple groups of patients who received dabigatran etexilate
within a single trial were pooled together while for secondary
analysis, only patients treated by dabigatran etexilate 150 mg
BID or 110 mg BID regimen were included versus the control
group. The control group was deﬁned as patients receiving any
drug regimen other than dabigatran etexilate.
Assessment of the Quality of the Included
Studies
To ascertain the validity of the eligible randomized trials, pairs
of reviewers (JD and FB), working independently, assessed
study quality using a validated scale (Jadad score)13 based on
the following criteria: method used to generate the random-
ization sequence, method of double blinding, and description
of patient withdrawals and dropouts. A score of 1 point was
given for each criterion satisﬁed and 1 additional point for
high-quality randomization and double blinding, for a maxi-
mum of 5 points. Studies with a score >2 were considered
high quality and studies with a score ≤2 points were
considered low quality.
Statistical Analysis
We performed the analysis using a ﬁxed-effect model and a
random-effect model to give all relevant results even when the
heterogeneity might be high. For the ﬁxed-effect model, the
odds ratio (OR) and 95% CI were calculated with the use of the
Peto method since there were few events in the included
trials.14,15 This method, also known as the 1-step method,
works on the log OR scale and is a variant of the basic
inverse-variance approach. Thus, the use of this method
allows calculation of an OR even with zero events in 1
treatment arm. However, trials in which patients had no
outcome of interest in either group were excluded from
analyses because OR cannot be calculated with the Peto
method in this case.14 It has been shown that the Peto
method provides the least biased and most powerful resultsT
ab
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Table 2. Summary of the Odds Ratios for the Different Analysis Using the Fixed-Effect Model (Using the Peto Method) or the
Random-Effect Model (Using the Inverse-Variance Method)
Odds Ratios (95% CI)
Heterogeneity for the Fixed-
Effect Model
Fixed-Effect Model
(Peto Method) P Value
Random-effect model
(Inverse-Variance Method) P Value I2 Statistics
Q Test
P Value
Myocardial infarction
Any dose vs any control treatments 1.34 (1.08 to 1.65) 0.007 1.30 (1.04 to 1.63) 0.021 0 0.577
Any dose vs enoxaparin 0.96 (0.57 to 1.60) 0.869 0.95 (0.57 to 1.59) 0.849 0 0.869
Any dose vs warfarin 1.41 (1.11 to 1.80) 0.005 1.38 (1.06 to 1.78) 0.015 22.990 0.261
Any dose vs placebo 1.67 (0.76 to 3.69) 0.202 1.84 (0.69 to 4.89) 0.222 0 0.689
150 mg BID vs any control treatments 1.45 (1.11 to 1.91) 0.007 1.41 (1.06 to 1.86) 0.018 13.558 0.328
150 mg BID vs enoxaparin NA NA NA NA
150 mg BID vs warfarin 1.43 (1.08 to 1.89) 0.014 1.77 (0.89 to 3.52) 0.105 43.173 0.152
150 mg BID vs placebo 1.89 (0.66 to 5.41) 0.239 1.91 (0.63 to 5.77) 0.254 0 0.613
110 mg BID vs any control treatments 1.33 (0.99 to 1.77) 0.057 1.33 (0.99 to 1.78) 0.058 0 0.760
110 mg BID vs enoxaparin NA NA NA NA
110 mg BID vs warfarin NA NA NA NA
110 mg BID vs placebo NA NA NA NA
Other cardiovascular events
Any dose vs any control treatments 0.93 (0.83 to 1.06) 0.270 0.94 (0.83 to 1.05) 0.270 0 0.963
Any dose vs enoxaparin NA NA NA NA
Any dose vs warfarin 0.94 (0.83 to 1.06) 0.293 0.94 (0.83 to 1.06) 0.293 0 0.873
Any dose vs placebo NA NA NA NA
150 mg BID vs any control treatments 0.95 (0.82 to 1.09) 0.423 0.94 (0.82 to 1.09) 0.423 0 0.962
150 mg BID vs enoxaparin NA NA NA NA
150 mg BID vs warfarin 0.95 (0.82 to 1.09) 0.454 0.95 (0.82 to 1.09) 0.454 0 0.879
150 mg BID vs placebo NA NA NA NA
110 mg BID vs any control treatments 0.91 (0.79 to 1.05) 0.206 0.91 (0.79 to 1.05) 0.208 0 0.455
110 mg BID vs enoxaparin NA NA NA NA
110 mg BID vs warfarin NA NA NA NA
110 mg BID vs placebo NA NA NA NA
Major bleeding
Any dose vs any control treatments 0.88 (0.79 to 0.99) 0.029 0.90 (0.75 to 1.08) 0.241 24.232 0.192
Any dose vs enoxaparin 1.07 (0.78 to 1.47) 0.685 1.04 (0.68 to 1.61) 0.847 41.876 0.142
Any dose vs warfarin 0.85 (0.75 to 0.96) 0.007 0.85 (0.76 to 0.96) 0.007 0 0.495
Any dose vs placebo 2.03 (0.82 to 5.06) 0.128 2.24 (0.73 to 6.90) 0.160 0 0.639
150 mg BID vs any control treatments 0.92 (0.81 to 1.05) 0.228 0.91 (0.67 to 1.23) 0.520 42.907 0.105
150 mg BID vs Enoxaparin NA NA NA NA
150 mg BID vs warfarin 0.90 (0.79 to 1.02) 0.101 0.84 (0.68 to 1.05) 0.129 19.506 0.292
150 mg BID vs placebo 2.86 (0.71 to 11.47) 0.139 2.62 (0.59 to 11.56) 0.205 0 0.450
110 mg BID vs any control treatments 0.82 (0.71 to 0.95) 0.007 1.41 (0.33 to 5.97)* 0.644* 77.276* 0.036*
110 mg BID vs enoxaparin NA NA NA NA
110 mg BID vs warfarin NA NA NA NA
110 mg BID vs placebo NA NA NA NA
Continued
DOI: 10.1161/JAHA.113.000515 Journal of the American Heart Association 8
Evaluation of Beneﬁt/Risk of Dabigatran Etexilate Douxﬁls et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at BIBL UNIV MORETUS PLANTIN on June 15, 2014http://jaha.ahajournals.org/Downloaded from 
when applied to simulated sparse event data with less
extreme group imbalances that are typically observed in RCT
designs.14 For the random-effect model, we used a basic
inverse-variance analysis. In case that 1 of the arms of 1 study
has zero events, 0.5 is added to all cells of the study results
table.14 However, it has been previously asked whether the
assumption of the within-study normal distribution is appro-
priate in case of sparse events. Effectively, in case where the
majority or all studies have few events, the choice of the
continuity correction really matters.16 Nevertheless, this
method is conceptually simpler and has been proved to work
well in cases where there are enough events. In the present
study, only a minority of the studies has zero cells so the
kind of continuity correction will not matter much and
the application of a basic inverse-variance analysis can be
justiﬁed.
The different comparators had different durations in follow-
up, but within a speciﬁc comparator, the durations in follow-
up were broadly similar (ie, short-term duration: <2 months or
long-term duration: ≥6 months). Therefore, the use of ORs
represents a valid approach to assess the risk associated with
the use of dabigatran etexilate. All reported P values were
2-sided.
When applicable, one-way sensitivity analyses were per-
formed by removing a single study, one at the time, to assess
the stability of the results. This technique was used in a
previous meta-analysis.17
Statistical heterogeneity across the various trials was
tested using Cochran’s Q statistic and quantiﬁed using the I2
value, which indicated the proportion of variability across
studies that was due to heterogeneity rather than sampling
error. Because there are few studies, Cochran’s Q test is not
effective at detecting heterogeneity if present. For this
reason, a P value of <0.10 is often used to indicate
heterogeneity rather than the conventional cut-point of
P=0.05. The I2 is less dependent on the number of studies.
I2 values of 25%, 50%, and 75% would mean low,
medium, and high heterogeneity, respectively. Based on this
measure of heterogeneity, we proposed a ﬁxed-effect model
or a random-effect model when applicable. Thus, when the
heterogeneity is >50% when using the I2 statistics or when the
Q test statistic is <0.10, it is preferable to refer to the
random-effect analysis. Otherwise, the use of the ﬁxed-effect
model should be recommended.
To investigate whether publication bias might affect the
validity of the estimates, funnel plots were constructed.
Funnel plot asymmetry was assessed by the method of
Egger’s linear regression test, a linear regression approach to
measure funnel plot asymmetry on the natural logarithm scale
of OR. The signiﬁcance of the intercept was determined by the
t-test suggested by Egger (P<0.05 was considered represen-
tative of statistically signiﬁcant publication bias). The Begg
and Mazumdar rank correlation test has also been performed
to assess an eventual publication bias. Data were analyzed
Table 2. Continued
Odds Ratios (95% CI)
Heterogeneity for the Fixed-
Effect Model
Fixed-Effect Model
(Peto Method) P Value
Random-effect model
(Inverse-Variance Method) P Value I2 Statistics
Q Test
P Value
All-cause mortality
Any dose vs any control treatments 0.89 (0.80 to 1.00) 0.041 0.89 (0.80 to 0.99) 0.033 11.026 0.339
Any dose vs enoxaparin 2.24 (0.68 to 7.39) 0.186 1.55 (0.38 to 6.39) 0.542 8.532 0.350
Any dose vs warfarin 0.90 (0.81 to 1.01) 0.061 0.90 (0.81 to 1.01) 0.061 0 0.813
Any dose vs placebo 0.47 (0.23 to 0.947) 0.035 0.54 (0.29 to 1.00) 0.050 0 0.354
150 mg BID vs any control treatments 0.88 (0.78 to 1.00) 0.045 0.88 (0.78 to 1.00) 0.049 0 0.636
150 mg BID vs enoxaparin NA NA NA NA
150 mg BID vs warfarin 0.89 (0.79 to 1.01) 0.078 0.89 (0.79 to 1.01) 0.079 0 0.955
150 mg BID vs placebo 0.48 (0.21 to 1.09) 0.078 0.48 (0.20 to 1.16) 0.105 0 0.341
110 mg BID vs any control treatments 0.90 (0.79 to 1.02) 0.103 0.74 (0.40 to 1.39)* 0.354* 57.176* 0.126*
110 mg BID vs enoxaparin NA NA NA NA
110 mg BID vs warfarin NA NA NA NA
110 mg BID vs placebo NA NA NA NA
Results are given for all stratiﬁcations proposed in this meta-analysis. Results of the heterogeneity are also provided to facilitate the choice of the best model effect.
*A heterogeneity for the ﬁxed-effect model above 50% using the I2 statistics, or below 0.10 using the Q test, should suggest the use of a random-effect model.
NA indicates not applicable.
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with the use of Comprehensive Meta-Analysis software,
version 2.2.046 (Biostat).
Results
Selected Studies
We screened 501 abstracts from the 3 different databases:
PubMed (70 sources), Scopus (401 sources), and The
Cochrane Database–Trials Results (48 sources). Two
abstracts were found from abstracts published in the past
2 years at international congresses (1 from the American
Heart Association and 1 from the American Society of
Haematology). One abstract (the RE-COVER II study) has
become published as a full-text article after the deadline
inclusion. Data were therefore extracted from the article to
provide the most relevant and up-to-date information.18 After
the abstracts were read, 35 articles were included for further
analysis. After duplicates and ineligible articles were
removed, 13 articles (for a total of 14 RCTs; 1 article
reports the results of 2 RCTs) met the predeﬁned inclusion
criteria of having a randomized comparator group, a similar
duration of treatment in all groups, and the presence of a
treatment arm featuring the use of dabigatran etexilate and
a control arm with comparator use (Figure 1). Two of the
14 trials did not report numerically interpretable MI
events.7,19,20 Only 4 studies reported other cardiovascular
events.1,10–12 Three of the 14 trials did not report mortality
information.20–22 No supplementary information was
obtained from the investigators, and therefore these trials
were not included in the analysis of MI and all-cause
mortality. Outcome of major bleeding was available for all
trials. Table 1 lists the 14 trials included in this meta-
analysis. All of these studies were published in peer-
reviewed journals as full articles.5,8,10–12,18,20–26 Data from
these trials were also reported in a summary fashion on a
clinical trial registry website maintained by the drug
manufacturer Boerhinger Ingelheim.27
Baseline Characteristics
Table 1 reports the doses of dabigatran etexilate and
comparator; the design of the study and the population; the
treatment duration; the efﬁcacy, safety, and cardiac out-
comes; and the Jadad score of included studies. All studies
gave a Jadad score of 5, except the PETRO, RE-LY, and RE-
DEEM trials.10,22,25 For the PETRO trial, the method used to
generate the sequence of randomization was not described
and the study was described as double-blind but the method
of blinding was inappropriate (open-label for warfarin). For the
RE-LY trial, the study was described as double-blind but the
method of blinding was inappropriate (open-label for warfarin).
For the RE-DEEM trial, the method of blinding was not
described.
MI, Other Cardiovascular Events, Major
Bleedings, and All-Cause Mortality
Table 2 reports all ORs for the ﬁxed-effect model analysis
using the Peto method and for the random-effect model
analysis using the inverse-variance method. It also includes
testing results for heterogeneity for the risk of MI, other
cardiovascular events, major bleeding, and all-cause mortality.
Myocardial Infarction
Data for MI were available for 12 studies.1,5,8,10–12,18,22–24,26
Figure 2A provides the forest plot for MI stratiﬁed by compar-
ator. Table 3 reports all MI events in the included trials. MI
occurred in 294 (1.16%) of 25 286 patients treated with
dabigatran etexilate and in 108 (0.72%) of 14 909 patients
treated with controls. The use of dabigatran etexilate was
associated with a signiﬁcant increase of MI (Peto odds ratio
(ORPETO) 1.34, 95% CI 1.08 to 1.65, I
2=0%, Q test P=0.577).
When compared with warfarin regimen, MI occurred in 218
(1.31%) of 16 686 patients treated with dabigatran etexilate
and in 80 (0.79%) of 10 157 patients treated with control
(ORPETO 1.41, 95% CI 1.11 to 1.80, I
2=23%, Q test P=0.261).
The 150-mg BID dosage was associated with a higher risk of MI
(ORPETO 1.45, 95% CI 1.11 to 1.91, I
2=14%, Q test P=0.328).
When compared with warfarin, the ORPETO for MI with the 150-
mg BID dosage was 1.43 (95% CI 1.08 to 1.89, I2=43%, Q test
P=0.152) (Figure 3A). Regarding the 110-mg BID dosage, the
ORPETO is 1.33 (95% CI 0.99 to 1.77, I
2=0%, Q test P=0.760).
Overall one-way sensitivity analysis shows that similar
results are obtained regardless of which study is excluded
from the primary analysis, even when RE-LY is removed (see
Figure S1A). All one-way sensitivity analyses preserve a
signiﬁcant increase of MI associated with dabigatran etexilate
when compared with warfarin (see Figure S2A).
Other Cardiovascular Events
Other cardiovascular events were provided in only 4 RCTs (in
the RE-DEEM, RE-LY, RE-COVER, and RE-MEDY studies).
Table 4 mentions all other cardiovascular events reported in
the included trials. There were 844 (5.18%) of 16 284 and 432
(4.76%) of 9085 in the dabigatran etexilate and comparator
groups, respectively. No results were statistically signiﬁcant
(Table 2). A forest plot comparing dabigatran etexilate or
dabigatran etexilate at the dosage of 150 mg BID with any
control treatment is provided in Figures 2B and 3B, respec-
tively. One-way sensitivity analysis reveals similar results
regardless of what study is removed from the result (see
Figures S1B and S2B).
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Group by
Control Treatment
Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
Enoxaparin RE-NOVATE 0,709 0,292 1,726 -0,757 0,449 33,23
Enoxaparin RE-MODEL 1,246 0,409 3,795 0,387 0,699 21,18
Enoxaparin RE-NOVATE II 0,993 0,062 15,888 -0,005 0,996 3,42
Enoxaparin RE-MOBILIZE 1,060 0,482 2,335 0,146 0,884 42,18
968,0561,0-995,1475,0859,0nirapaxonE
181,0833,1010,4077,0757,1MEED-ERobecalP 91,86
489,0020,0-165,51160,0279,0ETANOS-ERobecalP 8,14
202,0772,1396,3957,0476,1obecalP
550,0229,1756,1599,0482,1YL-ERnirafraW 89,90
475,0165,0736,281650,0981,3ORTEPnirafraW 0,36
814,0118,0526,9193,0049,1REVOC-ERnirafraW 2,28
700,0417,2238,61775,1251,5YDEM-ERnirafraW 4,17
912,0032,1805,05704,0635,4NGILA-ERnirafraW 1,01
804,0728,0457,9693,0669,1II REVOC-ERnirafraW 2,28
500,0187,2597,1701,1904,1nirafraW
700,0696,2056,1280,1633,1llarevO
0,1 0,2 0,5 1 2 5 10
Fav ours Dabigatran (any dose) Fav ours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
627,0053,0-865,1425,0709,0MEED-ERobecalP 100,00
627,0053,0-865,1425,0709,0obecalP
872,0680,1-750,1328,0339,0YL-ERnirafraW 99,29
799,0400,0-809,51260,0499,0REVOC-ERnirafraW 0,20
756,0444,0206,8852,0884,1YDEM-ERnirafraW 0,50
392,0150,1-950,1628,0539,0nirafraW
072,0201,1-550,1728,0439,0llarevO
0,1 0,2 0,5 1 2 5 10
Fav ours Dabigatran (any dose) Fav ours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
Enoxaparin RE-NOVATE 1,055 0,603 1,848 0,189 0,850 32,24
Enoxaparin RE-MODEL 1,060 0,481 2,337 0,145 0,884 16,19
Enoxaparin RE-NOVATE II 1,541 0,678 3,506 1,032 0,302 14,97
Enoxaparin RE-MOBILIZE 0,384 0,158 0,935 -2,107 0,035 12,79
Enoxaparin BISTRO II 1,500 0,782 2,877 1,219 0,223 23,82
586,0604,0864,1777,0860,1nirapaxonE
643,0149,0285,5745,0747,1MEED-ERobecalP 61,67
361,0593,1202,511054,0691,7ETANOS-ERobecalP 10,82
735,0716,0648,9403,0927,1ijuFobecalP 27,51
821,0225,1650,5618,0130,2obecalP
620,0232,2-389,0467,0668,0YL-ERnirafraW 88,39
624,0697,0573,65281,0302,3ORTEPnirafraW 0,17
135,0726,0-005,1554,0628,0REVOC-ERnirafraW 3,96
940,0869,1-799,0772,0625,0YDEM-ERnirafraW 3,43
652,0531,1-413,1953,0786,0II REVOC-ERnirafraW 3,34
274,0917,0558,6014,0676,1NGILA-ERnirafraW 0,71
700,0207,2-659,0457,0948,0nirafraW
920,0881,2-789,0297,0488,0llarevO
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (any dose) Favours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
Enoxaparin RE-NOVATE 4,483 0,819 24,531 1,730 0,084 49,36
Enoxaparin RE-MODEL 0,999 0,090 11,036 -0,001 1,000 24,72
Enoxaparin RE-NOVATE II 0,134 0,003 6,759 -1,005 0,315 9,28
Enoxaparin RE-MOBILIZE 4,545 0,243 84,961 1,013 0,311 16,63
681,0223,1983,7876,0832,2nirapaxonE
170,0408,1-060,1542,0015,0MEED-ERobecalP 93,48
151,0534,1-201,2800,0131,0ETANOS-ERobecalP 6,52
530,0111,2-749,0032,0764,0obecalP
360,0068,1-600,1697,0598,0YL-ERnirafraW 89,74
689,0810,0-038,1045,0499,0REVOC-ERnirafraW 3,30
137,0443,0-027,1264,0198,0YDEM-ERnirafraW 2,84
879,0820,0467,1675,0800,1II REVOC-ERnirafraW 3,91
912,0032,1-554,2020,0022,0NGILA-ERnirafraW 0,21
160,0478,1-500,1508,0009,0nirafraW
140,0840,2-599,0008,0298,0llarevO
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (any dose) Favours Control Treatments
A
B
C
D
Figure 2. Forest plot of the included studies for the risk of (A) myocardial infarction, (B) other cardiovascular
events, (C) major bleeding, and (D) all-cause mortality (ﬁxed-effect model analyses using the Peto method).
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Major Bleeding
Figure 2C provides a forest plot for major bleeding stratiﬁed
by comparator. Table 5 reports all major bleeding events
mentioned in the included trials. Major bleeding occurred in
955 (3.51%) of 27 231 patients treated with dabigatran
etexilate and in 553 (3.59%) of 15 425 patients treated with
controls. Use of dabigatran etexilate was associated with a
signiﬁcant reduction of major bleeding (ORPETO 0.88, 95% CI
0.79 to 0.99, I2=24%, Q test P=0.192). Compared with
warfarin regimen, major bleeding occurred in 800 (4.79%) of
16 686 of patients treated with dabigatran etexilate and in
494 (4.86%) of 10 157 patients treated with warfarin. The
ORPETO for major bleeding versus warfarin regimen was 0.85
(95% CI 0.75 to 0.96, I2=0%, Q test P=0.495). Figure 3B
reports the overall ORPETO for the 150-mg BID dosage
according to the comparator. No results are statistically
signiﬁcant. Regarding the 110-mg BID dosage, the ORPETO was
0.82 (95% CI 0.71 to 0.95, I2=77%, Q test P=0.036). However,
when using the random-effect model, the ORinverse-variance was
1.41 and not statistically signiﬁcant (95% CI, 0.33 to 5.97).
For the main analysis, overall one-way sensitivity analysis
showed that similar results were obtained regardless of which
study was excluded except when RE-LY, RE-MEDY, or RE-
MOBILIZE was removed, when a trend of a reduction in the
Table 3. Rates of Myocardial Infarction Across the Included Studies, Stratiﬁed by Comparator
Study
Dabigatran
Etexilate Control Odds Ratio (95% CI) Relative Weight (%)
No. of Events/Total No. (%) Fixed-Effect Model Random-Effect Model
Fixed-Effect
Model
Random-Effect
Model
BISTRO II21 (NCT01225822) 2004 No myocardial infarction reported
RE-NOVATE23 (NCT00168818)
2007
13/2309 (0.56) 9/1154 (0.78) 0.71 (0.29 to 1.73) 0.72 (0.31 to 1.69) 5.62 6.90
RE-MODEL24 (NCT00168805)
2007
10/1382 (0.72) 4/694 (0.58) 1.25 (0.41 to 3.80) 1.26 (0.39 to 4.02) 3.58 3.71
RE-MOBILIZE5 (NCT00152971)
2009
19/1728 (1.10) 9/868 (1.04) 1.06 (0.48 to 2.34) 1.06 (0.48 to 2.36) 7.14 7.90
RE-NOVATE II26 (NCT00657150)
2011
1/1010 (0.10) 1/1003 (0.10) 0.99 (0.06 to 15.89) 0.99 (0.06 to 15.90) 0.58 0.65
Overall enoxaparin 43/6429 (0.67) 23/3719 (0.62) 0.96 (0.57 to 1.60)
P=0.869
0.95 (0.57 to 1.59)
P=0.849
16.92 19.16
PETRO22 (NCT01227629) 2007 2/445 (0.45) 0/70 (0.00) 3.19 (0.06 to
182.64)
0.80 (0.04 to 16.73) 0.27 0.54
RE-LY25 (NCT00262600) 2009 195/12 091
(1.61)
75/6022 (1.25) 1.28 (1.00 to 1.66) 1.30 (0.99 to 1.70) 68.31 69.83
RE-COVER11 (NCT00291330) 2009 4/1273 (0.31) 2/1266 (0.16) 1.94 (0.39 to 9.63) 1.99 (0.36 to 10.90) 1.73 1.74
RE-MEDY12 (NCT00291330) 2013 10/1430 (0.70) 1/1426 (0.07) 5.15 (1.58 to 16.83) 10.04 (1.28 to
78.50)
3.17 1.19
RE-ALIGN8 (NCT01452347) 2013 3/168 (0.02) 0/84 (0.00) 4.54 (0.41 to 50.51) 3.57 (0.18 to 70.00) 0.77 0.57
RE-COVER II18 (NCT00680186)
2011
4/1279 (0.31) 2/1289 (0.16) 1.97 (0.40 to 9.75) 2.02 (0.37 to 11.04) 1.73 1.74
Overall warfarin 218/16 686
(1.31)
80/10 157
(0.79)
1.41 (1.11 to 1.80)
P=0.005
1.38 (1.06 to 1.78)
P=0.015
75.98 75.61
Fuji20 (NCT00246025) 2010 No myocardial infarction reported
RE-DEEM10 (NCT00621855) 2011 32/1490 (2.15) 4/371 (1.08) 1.76 (0.77 to 4.01) 2.01 (0.71 to 5.73) 6.52 4.59
RE-SONATE12 (NCT00558259)
2013
1/681 (0.15) 1/662 (0.15) 0.97 (0.06 to 15.56) 0.97 (0.06 to 15.57) 0.58 0.65
Overall placebo 33/2171 (1.52) 5/1033 (0.48) 1.67 (0.76 to 3.69)
P=0.202
1.84 (0.69 to 4.89)
P=0.222
7.10 5.24
Overall 287/23 839
(1.20)
106/13 536
(0.78)
1.34 (1.08 to 1.65)
P=0.007
1.30 (1.04 to 1.63)
P=0.021
100.00 100.00
For the pooled results of 1 comparator, the odds ratio is provided for a ﬁxed-effect model using the Peto method and for a random-effect model using the inverse-variance method. Relative
weight of each study is also mentioned for these 2 different models. NA indicates not applicable.
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Group by
Control Treatment
Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
002,0182,1895,6476,0801,2MEED-ERobecalP 85,52
489,0020,0-165,51160,0279,0ETANOS-ERobecalP 14,48
932,0771,1314,5656,0588,1obecalP
301,0136,1637,1159,0582,1YL-ERnirafraW 88,08
814,0118,0526,9193,0049,1REVOC-ERnirafraW 3,11
700,0417,2238,61775,1251,5YDEM-ERnirafraW 5,69
804,0728,0457,9693,0669,1II REVOC-ERnirafraW 3,11
410,0764,2398,1670,1724,1nirafraW
700,0786,2019,1701,1454,1llarevO
0,1 0,2 0,5 1 2 5 10
Fav ours Dabigatran (150 mg) Fav ours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relative 
odds ratio limit limit Z-Value p-Value weight
537,0833,0-387,1144,0788,0MEED-ERobecalP 100,00
537,0833,0-387,1144,0788,0obecalP
134,0887,0-980,1818,0449,0YL-ERnirafraW 99,08
799,0400,0-809,51260,0499,0REVOC-ERnirafraW 0,26
756,0444,0206,8852,0884,1YDEM-ERnirafraW 0,66
454,0847,0-290,1128,0749,0nirafraW
324,0108,0-680,1228,0549,0llarevO
0,1 0,2 0,5 1 2 5 10
Fav ours Dabigatran (150 mg) Fav ours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relativ e 
odds ratio limit limit Z-Value p-Value weight
Enoxaparin BISTRO II 1,998 0,887 4,501 1,670 0,095 100,00
590,0076,1105,4788,0899,1nirapaxonE
Placebo RE-DEEM 2,095 0,420 10,447 0,902 0,367 74,87
Placebo RE-SONATE 7,196 0,450115,202 1,395 0,163 25,13
931,0084,1374,11117,0758,2obecalP
Warfarin RE-LY 0,935 0,811 1,077 -0,928 0,353 86,70
Warfarin RE-COVER 0,826 0,455 1,500 -0,627 0,531 4,91
Warfarin RE-MEDY 0,526 0,277 0,997 -1,968 0,049 4,25
Warfarin RE-COVER II 0,687 0,359 1,314 -1,135 0,256 4,14
101,0046,1-220,1587,0598,0nirafraW
822,0702,1-150,1118,0329,0llarevO
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (150 mg) Favours Control Treatments
Group by
Control Treatment
Study name Statistics for each study Peto odds ratio and 95%  CI
Peto Lower Upper Relativ e
odds ratio limit limit Z-Value p-Value weight
Placebo RE-DEEM 0,539 0,226 1,284 -1,395 0,163 91,08
Placebo RE-SONATE 0,131 0,008 2,102 -1,435 0,151 8,92
870,0067,1-880,1802,0574,0obecalP
Warfarin RE-LY 0,883 0,772 1,010 -1,818 0,069 87,15
Warfarin RE-COVER 0,994 0,540 1,830 -0,018 0,986 4,22
Warfarin RE-MEDY 0,891 0,462 1,720 -0,344 0,731 3,63
Warfarin RE-COVER II 1,008 0,576 1,764 0,028 0,978 5,00
870,0067,1-310,1987,0498,0nirafraW
540,0300,2-799,0977,0188,0llarevO
0,1 0,2 0,5 1 2 5 10
Favours Dabigatran (150 mg) Favours Control Treatments
A
B
C
D
Figure 3. Forest plot of the included studies for the risk of (A) myocardial infarction, (B) other cardiovascular events, (C) major
bleeding, and (D) all-cause mortality with the 150-mg BID dosage regimen (ﬁxed-effect model analyses using the Peto method).
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risk of major bleeding was maintained but no longer
statistically signiﬁcant (see Figure S1C). All one-way sensitiv-
ity analyses preserved a signiﬁcant reduction in the risk of
major bleeding with dabigatran etexilate when compared with
warfarin except when RE-LY was removed (see Figure S2C).
All-Cause Mortality
Data for all-cause mortality were available in 11
studies.1,5,7,10–12,23,24,26 Figure 2D provides a forest plot for
all-causemortality stratiﬁed by comparator. Table 6 reports all-
cause mortality events in the included studies. Death occurred
in 990 (4.07%) of 24 330 patients treated with dabigatran
etexilate and in 572 (3.92%) of 14 582 patients treated with
controls. Use of dabigatran etexilate was associated with a
signiﬁcant reduction of all-cause mortality (ORPETO 0.89, 95% CI
0.80 to 1.00, I2=11%, Q test P=0.339). When compared with
warfarin regimen, all-causemortality occurred in 948 (5.84%) of
16 241 patients treated with dabigatran etexilate and in 554
(5.49%) of 10 087 patients treatedwithwarfarin. TheORPETO for
all-cause mortality versus warfarin regimen was 0.90 (95% CI
0.81 to 1.01, I2=0%, Q test P=0.813). There was a signiﬁcant
reduction of all-cause mortality with the 150-mg BID dosage
(OR 0.88, 95% CI 0.78 to 1.00, I2=0%, Q test P=0.636)
(Figure 3C). The 110-mg BID dosage showed an ORPETO of 0.90
(95% CI 0.79 to 1.02, I2=57%, Q test P=0.126). The use of a
random-effect model using the inverse-variancemethod did not
change the result, which was also nonsigniﬁcant.
Overall one-way sensitivity analysis showed that similar
results were obtained regardless of which study was excluded
except when RE-LY and RE-DEEM were removed, when a trend
Table 4. Rates of Other Cardiovascular Events Across the Included Studies, Stratiﬁed by Comparator
Study
Dabigatran
etexilate Control Odds Ratio (95% CI) Relative Weight (%)
No. of Events/Total No. (%) Fixed-Effect Model Random-Effect Model
Fixed-Effect
Model
Random-Effect
Model
BISTRO II21 (NCT01225822) 2004 No other cardiovascular events reported
RE-NOVATE23 (NCT00168818)
2007
No other cardiovascular events reported
RE-MODEL24 (NCT00168805)
2007
No other cardiovascular events reported
RE-MOBILIZE5 (NCT00152971)
2009
No other cardiovascular events reported
RE-NOVATE II26 (NCT00657150)
2011
No other cardiovascular events reported
Overall enoxaparin Not applicable
PETRO22 (NCT01227629) 2007 No other cardiovascular events reported
RE-LY25 (NCT00262600) 2009 774/12 091
(6.40)
411/6022
(6.83)
0.93 (0.82 to 1.06) 0.93 (0.83 to 1.06) 94.41 94.29
RE-COVER11 (NCT00291330) 2009 1/1273 (0.08) 1/1266 (0.08) 0.99 (0.06 to 15.91) 0.99 (0.06 to 15.92) 0.19 0.19
RE-MEDY12 (NCT00291330) 2013 3/1430 (0.21) 2/1426 (0.14) 1.49 (0.26 to 8.60) 1.50 (0.25 to 8.97) 4.92 5.07
RE-ALIGN8 (NCT01452347) 2013 No other cardiovascular events reported
RE-COVER18 ((NCT00680186)
2013
No other cardiovascular events reported
Overall warfarin 778/15 239
(5.10)
414/8784
(4.71)
0.94 (0.83 to 1.06)
P=0.293
0.94 (0.83 to 1.05)
P=0.293
99.52 99.52
Fuji20 (NCT00246025) 2010 No myocardial infarction reported
RE-DEEM10 (NCT00621855) 2011 66/1490 (4.43) 18/371 (4.85) 0.91 (0.52 to 1.57) 0.48 0.45
RE-SONATE12 (NCT00558259)
2013
No other cardiovascular events reported
Overall placebo Not applicable
Overall 844/16 284
(5.18)
432/9085
(4.76)
0.93 (0.83 to 1.06)
P=0.270
0.94 (0.83 to 1.05)
P=0.270
100.00 100.00
For the pooled results of 1 comparator, the odds ratio is provided for a ﬁxed-effect model using the Peto method and for a random-effect model using the inverse-variance method. Relative
weight of each study is also mentioned for these 2 different models. NA indicates not applicable.
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of a reduction in the risk of all-cause mortality was maintained
but no longer statistically signiﬁcant (see Figure S1D). All one-
way sensitivity analyses preserved a nonsigniﬁcant reduction
in the risk of all-cause mortality with dabigatran etexilate
compared with warfarin (see Figure S2D).
Figure S3A through S3D provides all funnel plot results
as well as the Egger’s test and the Begg and Mazumdar
rank correlation test. These did not reveal any publication
bias.
Discussion
The 2012, European Society of Cardiology guidelines for the
management of AF recommend the “new (or non-VKA) oral
anticoagulants,” or NOACs, as broadly preferable to VKAs in the
vast majority of patients with nonvalvular AF.28 The American
College of Chest Physicians Guidelines and the Canadian
Cardiovascular Society Guidelines took a similar approach.29,30
Today, deciding on the optimal oral anticoagulant is rather
Table 5. Rates of Major Bleeding Across the Included Studies, Stratiﬁed by Comparator
Study
Dabigatran Etexilate Control Odds Ratio (95% CI) Relative Weight (%)
No. of Events/Total No. (%) Fixed-Effect Model Random-Effect Model
Fixed-Effect
Model
Random-Effect
Model
BISTRO II21 (NCT01225822)
2004
50/1557 (3.21) 8/392 (2.04) 1.50 (0.78 to 2.88) 1.59 (0.75 to 3.39) 2.87 5.23
RE-NOVATE23
(NCT00168818) 2007
38/2309 (1.65) 18/1154 (1.56) 1.06 (0.60 to 1.85) 1.06 (0.60 to 1.86) 3.88 8.74
RE-MODEL24
(NCT00168805) 2007
19/1382 (1.37) 9/694 (1.30) 1.06 (0.48 to 2.34) 1.06 (0.48 to 2.36) 1.95 4.72
RE-MOBILIZE5
(NCT00152971) 2009
10/1728 (0.58) 12/868 (1.38) 0.38 (0.16 to 0.94) 0.42 (0.18 to 0.97) 1.54 4.26
RE-NOVATE II26
(NCT00657150) 2011
14/1010 (1.39) 9/1003 (0.90) 1.54 (0.68 to 3.51) 1.55 (0.67 to 3.60) 1.80 4.28
Overall enoxaparin 131/7986 (1.64) 56/4111 (1.36) 1.07 (0.78 to 1.47)
P=0.685
1.04 (0.68 to 1.61)
P=0.847
12.04 27.23
PETRO22 (NCT01227629)
2007
4/445 (0.90) 0/70 (0.00) 3.20 (0.18 to 56.38) 1.44 (0.08 to 26.98) 0.15 0.38
RE-LY25 (NCT00262600)
2009
741/12 091 (6.13) 421/6022 (6.99) 0.87 (0.76 to 0.98) 0.87 (0.77 to 0.98) 76.46 47.62
RE-COVER11 (NCT00291330)
2009
20/1273 (1.57) 24/1266 (1.90) 0.83 (0.46 to 1.50) 0.83 (0.45 to 1.50) 3.43 7.92
RE-MEDY12 (NCT00291330)
2013
13/1430 (0.91) 25/1426 (1.75) 0.53 (0.28 to 1.00) 0.51 (0.26 to 1.01) 2.97 6.42
RE-ALIGN8 (NCT01452347)
2013
7/168 (4.17) 2/84 (2.38) 1.68 (0.41 to 6.86) 1.78 (0.36 to 8.78) 0.61 1.26
RE-COVER II18
(NCT00680186) 2011
15/1280 (1.17) 22/1288 (1.71) 0.69 (0.36 to 1.31) 0.68 (0.35 to 1.32) 2.89 6.65
Overall warfarin 800/16 687 (4.79) 494/10 156 (4.86) 0.85 (0.75 to 0.96)
P=0.007
0.85 (0.76 to 0.96)
P=0.007
86.51 70.25
Fuji20 (NCT00246025) 2010 6/388 (1.55) 1/124 (0.81) 1.73 (0.30 to 9.85) 1.93 (0.23 to 16.20) 0.40 0.71
RE-DEEM10 (NCT00621855)
2011
16/1490 (1.07) 2/371 (0.54) 1.75 (0.55 to 5.58) 2.00 (0.46 to 8.75) 0.90 1.46
RE-SONATE12
(NCT00558259) 2013
2/681 (0.29) 0/662 (0.00) 7.20 (0.45 to 115.20) 4.88 (0.23 to 101.73) 0.16 0.35
Overall placebo 24/2559 (0.94) 3/1157 (0.26) 2.03 (0.82 to 5.06)
P=0.128
2.03 (0.82 to 5.06)
P=0.128
1.46 2.52
Overall 955/27 232 (3.51) 553/15 426 (3.59) 0.88 (0.79 to 0.99)
P=0.029
0.93 (0.75 to 1.15)
P=0.483
100.00 100.00
For the pooled results of 1 comparator, the odds ratio is provided for a ﬁxed-effect model using the Peto method and for a random-effect model using the inverse-variance method. Relative
weight of each study is also mentioned for these 2 different models. NA indicates not applicable.
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challenging. The absence of head-to-head trials precludes ﬁrm
conclusions as to which NOAC is best. However, dabigatran
etexilate at the dosage of 150mg BID alongwith apixaban 5 mg
or 2.5 mg BID and edoxaban 60 mg once daily are the only
NOACs that reduce stroke or systemic embolism in prospective
phase III RCT, which is the gold standard for recommendations
with respect to clinical use.4,25,31,32 Nonetheless, whatever is
the indication, patients treated with NOACs may present with
comorbidities such as coronary disease. In the RE-LY study, a
nonsigniﬁcant but small numerical increase in MI events with
dabigatran etexilate compared with warfarin was observed,25
which led some concerned clinicians to consider the use of a
VKA or an alternative NOAC (eg, rivaroxaban, apixaban, or
edoxaban) in patients with an ACS. This position was vigorously
debated. Thus, the 2010 Canadian Cardiovascular Society
guidelines33 included a caution against the use of dabigatran
etexilate in patients with AF who are at high risk of coronary
events. In the 2012 guidelines, their position concerning this
Table 6. Rates of All-Cause Mortality Across the Included Studies, Stratiﬁed by Comparator
Study
Dabigatran Etexilate Control Odds Ratio (95% CI) Relative Weight (%)
No. of Events/Total No. (%) Fixed-Effect Model Random-Effect Model
Fixed-Effect
Model
Random-Effect
Model
BISTRO II21 (NCT01225822)
2004
No information regarding the mortality was provided
RE-NOVATE23
(NCT00168818) 2007
6/2293 (0.26) 0/1142 (0.00) 4.48 (0.82 to 24.53) 6.49 (0.37 to 115.36) 0.41 0.14
RE-MODEL24 (NCT00168805)
2007
2/1371 (0.15) 1/685 (0.15) 1.00 (0.09 -11.04) 1.00 (0.09 to 11.04) 0.21 0.20
RE-MOBILIZE5
(NCT00152971) 2009
2/1253 (0.16) 0/643 (0.00) 4.55 (0.24 to 84.96) 2.57 (0.12 to 53.63) 0.14 0.12
RE-NOVATE II26
(NCT00657150) 2011
0/1001 (0.00) 1/992 (0.10) 0.13 (0.00 to 6.76) 0.33 (0.01 to 8.11) 0.08 0.11
Overall enoxaparin 10/5918 (0.17) 2/3462 (0.06) 2.24 (0.68 to 7.39)
P=0.186
1.55 (0.38 to 6.39)
P=0.542
0.84 0.57
PETRO22 (NCT01227629)
2007
No information regarding the mortality was provided
RE-LY25 (NCT00262600)
2009
884/12 091 (7.31) 487/6022 (8.09) 0.90 (0.80 to 1.01) 0.90 (0.80 to 1.01) 86.87 86.84
RE-COVER11 (NCT00291330)
2009
21/1273 (1.65) 21/1266 (1.66) 0.99 (0.54 to 1.83) 0.99 (0.54 to 1.83) 3.19 3.10
RE-MEDY12 (NCT00291330)
2013
17/1430 (1.19) 19/1426 (1.33) 0.89 (0.46 to 1.72) 0.89 (0.46 to 1.72) 2.75 2.66
RE-ALIGN8 (NCT01452347)
2013
1/168 (0.60) 2/84 (2.38) 0.22 (0.02 to 2.46) 0.25 (0.02 to 2.75) 0.20 0.20
RE-COVER II18
(NCT00680186) 2013
25/1279 (1.95) 25/1289 (1.94) 1.01 (0.58 to 1.76) 1.01 (0.58 to 1.76) 3.79 3.68
Overall warfarin 948/16 241 (5.84) 554/10 087 (5.49) 0.90 (0.81 to 1.01)
P=0.061
0.90 (0.81 to 1.01)
P=0.061
96.80 96.48
Fuji20 (NCT00246025) 2010 No information regarding the mortality was provided
RE-DEEM10 (NCT00621855)
2011
32/1490 (2.15) 14/371 (3.77) 0.51 (0.25 to 1.06) 0.56 (0.30 to 1.06) 2.21 2.83
RE-SONATE12
(NCT00558259) 2013
0/681 (0.00) 2/662 (0.30) 0.13 (0.01 to 2.10) 0.19 (0.01 to 4.05) 0.15 0.12
Overall placebo 32/2171 (1.47) 16/1033 (4.07) 0.47 (0.23 to 0.95)
P=0.035
0.47 (0.23 to 0.95)
P=0.035
2.36 2.95
Overall 990/24 330 (4.07) 572/14 582 (3.92) 0.89 (0.80 to 1.00)
P=0.041
0.89 (0.72 to 1.09)
P=0.252
100.00 100.00
For the pooled results of 1 comparator, the odds ratio is provided for a ﬁxed-effect model using the Peto method and for a random-effect model using the inverse-variance method. Relative
weight of each study is also mentioned for these 2 different models.
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alert has changed with the updated data of the RE-LY trials.1 In
contrast, no concern was raised in the 2011 guideline update of
the American College of Cardiology Foundation and the Heart
Rhythm Society atrial ﬁbrillation, as well as in the 2012
American Heart Association guideline update and 2012
European Society of Cardiology guidelines for the management
of AF.28,30,33–35
A recent Danish “everyday clinical practice” postapproval
clinical cohort study revealed that mortality, intracranial
bleeding, pulmonary embolism, and MI were lower with
dabigatran etexilate, compared with warfarin.36 The authors
acknowledged that this analysis was limited by its depen-
dence on prescribing information and that selection of
treatment option was inﬂuenced by patient characteristics
that might relate to outcome. In response, Sipahi et al
underlined that, while examination of observational adminis-
trative dataset may sometimes be helpful to answer certain
questions, the gold standard for determining drug safety and
efﬁcacy is careful analysis of all available RCTs.37 In their
analysis, they pooled 5 RCTs comparing dabigatran etexilate
with warfarin and found a 48% increase in the risk of MI.
However, they did not stratify their analysis by dose or other
comparators and the methodology was not presented.
Another previous meta-analysis, conducted by Uchino et al,3
showed limitations because it pooled data across trials with
different comparators without any stratiﬁcation analysis. In
addition, this previous meta-analysis used the outdated
dataset from the RE-LY study for the primary analysis and
obviously did not include data from recently conducted RCTs
(RE-MEDY, RE-SONATE, RE-ALIGN, and RE-COVER II). The
investigators also decided to not include the RE-MOBILIZE
study. However, another recently published meta-analysis
including the additional results of RE-LY conﬁrmed this
increase risk and provided stratiﬁcation according to the
indication of use.6 Nevertheless, no direct information about
the risk according to the comparator or the dabigatran
etexilate dose was provided.
Holnloser et al pointed out the need for a more-detailed
analysis of the effects of dabigatran on coronary events
against the different comparators.1 Therefore, the meta-
analysis, by giving stratiﬁcation by dose and comparator,
provides robust evidence that dabigatran etexilate is associ-
ated with an overall signiﬁcant 34% increase in the risk of MI
(Figure 2A). The risk was principally identiﬁed when warfarin
is used as comparator (41% increase for the ﬁxed-effect
model analysis; see Table 2 for comparison with the random
effect model). We also showed that in RCTs using the higher
licensed dabigatran etexilate dosage (ie, the 150-mg BID
dosage regimen), a signiﬁcant 45% overall increased risk of MI
was identiﬁed (Figure 3A). No ﬁrm conclusion can be taken
with the lower dabigatran etexilate dosage (110 mg BID)
because of the limited number of studies. However, a trend
toward an increased risk of MI (33%) was detected, which was
of borderline signiﬁcance (P=0.057). Two plausible explana-
tions for these ﬁndings can be considered: either dabigatran
etexilate is less efﬁcacious than warfarin for the prevention of
MI, or dabigatran etexilate causes acute coronary events.
Does Warfarin Protect Against MI?
Many studies have shown that the VKAs are useful drugs for
the management of patients with coronary artery disease.38,39
Thus, warfarin alone or with aspirin was shown to be superior
to aspirin alone in reducing the incidence of composite events
(death, nonfatal reinfarction, or thromboembolic cerebral
stroke) after an acute MI.39 In a previous review, Lip et al40
concluded that warfarin may result in a lower risk of MI
compared with other (nonwarfarin) anticoagulants or an
“anticoagulant equivalent (clopidogrel 75 mg and aspirin
300 mg).” In addition, speciﬁc recommendations from the
2013 ACCF/AHA Guideline for the Management of ST-
Elevation Myocardial Infarction mentioned that warfarin is
an option for treatment after MI to reduce the recurrence of
such events.41
Nonetheless, a pooled analysis of the SPORTIF program,42
evaluating ximelagatran versus warfarin in patients with
nonvalvular AF, showed similar rate of MI between the 2
groups. However, the results were heterogeneous by trial, and
in SPORTIF-III, there is a suggestion that ximelagatran
increases MI.43 Based on this analysis, the possibility that
warfarin may provide a protective effect against MI in patients
with nonvalvular AF cannot be excluded. However, the
underlying mechanisms supporting this potential beneﬁcial
effect need to be further investigated.44
Does Dabigatran Etexilate Cause MI?
Placebo-controlled trials provide the optimal method to
examine whether dabigatran etexilate causes coronary
events. Unfortunately, the results of the only large placebo-
controlled study of dabigatran etexilate in patients with
coronary artery disease were inconclusive. There were
numerically higher cases of MI in the dabigatran etexilate
arm in the RE-DEEM study, but this ﬁnding was not
statistically signiﬁcant. For the RE-SONATE study, similar
rates of MI were observed in both arms of the study.
If we suggest that dabigatran etexilate could cause MI,
therefore, the understanding of the potential underlying
mechanisms for the apparent increase in MI associated with
dabigatran etexilate is not straightforward. Platelet activation
and aggregation contribute to the underlying mechanisms of
coronary thrombosis. Therefore, a potential contributing
factor may be a direct or indirect effect on platelet activation.
In a phase II trial with DE (PETRO study, see Table 1), urinary
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11-dehydrothromboxane B2 concentrations, a marker of
platelet activation, were signiﬁcantly increased at any dabig-
atran etexilate doses. However, in other studies, dabigatran
showed no effect on ex vivo induced platelet aggregation and
inhibited platelet aggregation induced by a-thrombin.45,46
A more plausible explanation could be that the rupture of a
coronary plaque also triggers explosive thrombin generation.
As a stoichiometric inhibitor of thrombin, the possibility exists
that local concentrations of thrombin exceed those available
of dabigatran at the site of injury.
Results from different studies conducted with direct or
indirect thrombin inhibitors do not provide consistence evi-
dences of a class effect. Thus, in large, phase III trials, bivalirudin
and hirudin have been shown to be effective alternatives to
heparin for the management of ACS. They were associated with
a lower risk of MI.47 However, smaller phase II (ie, the ESTEEM
trial with ximelagatran) studies with univalent direct thrombin
inhibitors yielded contradictory results.44,48 Namely, while the
reduction composite outcome of death from any cause, stroke,
MI, and recurrent ischemic events was statistically signiﬁcant,
the reduction in MI taken alone was not.
It is suggested that if dabigatran etexilate is a cause of MI,
unstable angina would also be expected to increase. Based on
our ﬁndings, other cardiovascular events were not increased
(Table 2). However, it should be kept in mind that “other
cardiovascular events” may be contaminated by nonspeciﬁc
causes of chest pain, which would dilute any signal of
increased risk because such events are not expected to be
affected by dabigatran.
Implications for Patient Care and Regulators
This meta-analysis reveals that dabigatran signiﬁcantly
reduced major bleeding and all-cause mortality compared
with controls in the ﬁxed-effect analysis. However, while the
reduction of major bleeding is statistically signiﬁcant versus
warfarin, the reduction in all-cause mortality is not (Table 2).
Compared with warfarin, pooled results from any dabigatran
doses revealed a signiﬁcant 15% reduction of major bleeding
and a nonsigniﬁcant 10% reduction of all-cause mortality,
whereas the increase in MI reached 41%. The increased risk of
MI with the 150-mg BID dosage is signiﬁcant using a ﬁxed-
effect model (43%). For the 150-mg BID dosage, the reduction
in major bleeding and mortality is not statistically signiﬁcant
(Figure 3). Taken together, these ﬁndings may suggest that in
frail patients presenting with comorbidities (eg, patients aged
≥75 years or with creatinine clearance ≤50 mL/min, as
deﬁned previously),49 the choice of the 150-mg BID dosage
should be carefully discussed and the 110-mg BID dosage
(not available in the United States) might be considered.
Based on our results, it cannot be concluded that the 110-mg
BID dosage is associated with a higher risk of MI.
However, in terms of absolute risk, such an increased risk
of MI should be considered taking into account the outcomes
of stroke or systemic embolism, major bleeding, and all-cause
mortality. Thus, the results from the RE-LY trial showed that
the beneﬁts of dabigatran etexilate over warfarin for stroke
prevention, with the 150-mg BID dosage, or for the reduction
of major bleeding, with the 110-mg BID dosage, outweigh the
increase risk of MI (Table 7). Effectively, the risk difference
was greatly in favor of dabigatran etexilate regarding the
composite of stroke/systemic embolism, MI, major bleeding,
and all-cause mortality.
Moreover, we suggest that healthcare professionals and
regulators consider additional risk minimization to prevent the
risk of MI. The switch to a factor Xa inhibitor may be an
appropriate alternative. Indeed, in a recently published meta-
analysis evaluating the risk of MI with NOACs, rivaroxaban
signiﬁcantly reduced the risk of MI (OR 0.79, 95% CI 0.69 to
0.89, P<0.001), while apixaban showed no difference com-
pared with warfarin (OR 0.94, 95% CI 0.82 to 1.07, P=0.333).6
This was also found with edoxaban, where there is no
Table 7. Summary Data of the RE-LY Study
Outcome
warfarin (target
INR 2.0 to 3.0) Dabigatran Etexilate 110 mg BID Dabigatran Etexilate 150 mg BID
Rate per 1000
Person-Years
Rate per 1000
Person-Years
Risk Difference vs
warfarin per 1000
Person-Years
Rate per 1000
Person-Years
Risk Difference vs
warfarin per 1000
Person-Years
Stroke or systemic embolism 17.1 15.4 1.7 11.1 6.0
MI 5.9 7.8 1.9 7.7 1.8
Fatal MI 1.0 1.3 0.3 1.1 0.1
Major bleeding 35.7 28.7 7.0 33.2 2.5
Fatal major bleeding 3.3 1.9 1.4 2.3 1.0
All-cause mortality 41.3 37.5 3.8 36.4 4.9
MI indicates myocardial infarction.
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difference compared with warfarin (hazard ratio 0.94, 95% CI
0.74 to 1.19. P=0.60; and hazard ratio 1.19, 95% CI 0.95 to
1.49, P=0.13, for the low- and high-dose edoxaban, respec-
tively).32 Unlike dabigatran etexilate, twice-daily low-dose
rivaroxaban (2.5 mg or 5 mg) has been used with success in
ACS.50 However, there are no data on ACS prevention relating
to the dosage of rivaroxaban used in AF (20 mg daily), and we
should keep in mind that these studies were performed versus
placebo. There are no data comparing rivaroxaban in this
context versus active comparator. It is important to underline
that for long-term use, indications such as AF, and the
treatment of acute venous thromboembolism, these new
agents showed generally similar proﬁles in terms of efﬁcacy
and safety. Namely, in secondary prevention in nonvalvular
AF, apixaban, rivaroxaban, edoxaban, and dabigatran had
broadly similar efﬁcacies for the main end points, although
the end points of hemorrhagic stroke, vascular death, major
bleeding, and intracranial bleeding were less common with
dabigatran 110 mg BID than with rivaroxaban. In addition, we
should keep in mind that dabigatran etexilate 150 mg BID
along with apixaban 5 mg or 2.5 mg BID and edoxaban 60 mg
once daily are the only NOACs showing superiority compared
with warfarin in the NVAF setting for the outcome of stroke
and systemic embolism.25,31,32 For primary prevention,
dabigatran etexilate, rivaroxaban, and apixaban showed some
differences in relation to efﬁcacy and bleedings.51 In the
treatment of acute venous thromboembolism, NOACs had
similar efﬁcacy and mortality proﬁles compared with conven-
tional anticoagulation with VKAs, while rivaroxaban, apixaban,
and edoxaban were associated with a lower risk of major
bleeding.52–54 However, in the absence of head-to-head
studies, any comparison of the efﬁcacy and safety of these
NOACs should be interpreted with caution because of the
differences in study designs, protocols, and population
characteristics.
Strengths and Limitations of This Meta-analysis
This is the ﬁrst up-to-date meta-analysis that includes the
most recent studies with dabigatran etexilate that also
provides subgroup analysis by comparators and doses of
dabigatran etexilate. Sensitivity analysis conﬁrmed the
robustness of the results as well as the use of different
model effects. No evidence of publication bias and a low
heterogeneity was shown.
However, our study has important limitations. We per-
formed a meta-analysis using ORPETO from the individual
results of trials that were not originally intended to explore all
cardiovascular outcomes, except for RE-DEEM study, which
evaluated the beneﬁt of dabigatran etexilate in patients with
ACS treated with dual-antiplatelet therapy. In addition, in most
trials, the deﬁnition of MI was not available and in a
conservative purpose, we adjudicated ACS as MI when not
speciﬁcally described. We recognize that this might overesti-
mate the rate of MI and lead to adjudication bias because we
did not know if an ACS is a MI or, for example, unstable angina.
However, the analysis of other cardiovascular events did not
reveal any differences between dabigatran etexilate and
control treatments, reinforcing the hypothesis that dabigatran
is probably less effective than warfarin in the prevention of MI
where the amount of thrombin generated in a microenviron-
ment is higher. Another limitation of this study is that we did
not have access to original source/patient-level data for any of
these trials. Time-to-event data were not available in any
of these trials, except for RE-LY. This did not allow the use of
more statistically powerful time-to-event analysis. Globally, a
meta-analysis is always considered less convincing than a
large prospective trial designed to assess the outcome of
interest. At this time, to the best of our knowledge, such a trial
has not been completed for dabigatran etexilate (data source:
clinicaltrials.gov), and it is obvious that no RCT will be
undertaken to assess the comparative risk of MI.
Conclusions
This meta-analysis of RCTs provides evidence that dabigatran
etexilate is associated with an overall signiﬁcant 34% increase
in the risk of MI. The risk was principally identiﬁed when
warfarin is used as comparator (41% increase). No deﬁnitive
conclusion about the absence of the risk of MI with the lower
dabigatran etexilate dosage (110 mg BID) can be drawn at this
time. However, this increased risk should be considered
taking into account the overall beneﬁt of dabigatran etexilate,
especially in patients with NVAF. In conclusion, we suggest
that healthcare professionals and regulators should consider
additional risk minimization strategies to prevent the risk of
MI in vulnerable populations.
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None.
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